Celyad Oncology SA (CIK: 0001637890) EDGAR, Information, Filings... CompaniesBIO.Com

Celyad Oncology SA

Mailing address
RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, Belgium, 1435
Phone
32 10 394 100
State location
Belgium
State of incorporation
Belgium
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Celyad Oncology SA (CIK: 0001637890) is an American company incorporated in the state of Belgium. Head office is located at RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, Belgium, 1435. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Celyad Oncology SA is a public company and trade via Over-The-Counter (OTC).

Old names:

CELYAD S.A. from 2015-28-Apr to 2020-07-May
CARDIO3 BIOSCIENCES S.A. from 2015-31-Mar to 2015-31-Mar

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Celyad Oncology SA

Filings	Format	Description	Filed/Effective	File/Film Number
15F-12B	Document	Notice of termination of a foreign private issuer’s registration of a class of securities under Section 12(b) Acc-no: 0001193125-24-029044 (34 Act) Size: KB	Feb-09-2024	001-37452 24611006
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-24-008898 (34 Act) Size: KB	Jan-17-2024	001-37452 24536670
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-300354 (34 Act) Size: KB	Dec-21-2023	001-37452 231502744
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-297421 (34 Act) Size: KB	Dec-18-2023	001-37452 231492846
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-288212 (34 Act) Size: KB	Dec-04-2023	001-37452 231462136
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-288210 (34 Act) Size: KB	Dec-04-2023	001-37452 231462130
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-282600 (34 Act) Size: KB	Nov-24-2023	001-37452 231435150
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-281483 (34 Act) Size: KB	Nov-21-2023	001-37452 231428078
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-281101 (34 Act) Size: KB	Nov-21-2023	001-37452 231424549
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-277929 (34 Act) Size: KB	Nov-15-2023	001-37452 231411102
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-264888 (34 Act) Size: KB	Oct-27-2023	001-37452 231354747
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-241789 (34 Act) Size: KB	Sep-26-2023	001-37452 231277103
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-239989 (34 Act) Size: KB	Sep-22-2023	001-37452 231270198
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-236497 (34 Act) Size: KB	Sep-18-2023	001-37452 231260041
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-233872 (34 Act) Size: KB	Sep-13-2023	001-37452 231251576
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-231921 (34 Act) Size: KB	Sep-11-2023	001-37452 231246624
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-228984 (34 Act) Size: KB	Sep-06-2023	001-37452 231237775
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001341004-23-000227 (34 Act) Size: KB	Sep-05-2023	005-90813 231236265
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-228030 (34 Act) Size: KB	Sep-05-2023	001-37452 231234057
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001193125-23-220581 (34 Act) Size: KB	Aug-25-2023	001-37452 231203747

Recent 20 filings. View all Celyad Oncology SA filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Celyad Oncology SA overview
Celyad Oncology SA job
Celyad Oncology SA stock
Celyad Oncology SA ownership
Celyad Oncology SA CEO
Celyad Oncology SA documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.